The CDCN provides grant funding to support research on the etiology, pathogenesis, diagnosis, and management of Castleman disease.
It is a database of clinical information drawn from patients diagnosed with Castleman disease and includes symptoms, laboratory tests, imaging, pathology, and treatment approaches.
[5] The Castlebank is a collaboration between the CDCN and the University of Pennsylvania to house a centralized biobank of tissue samples donated by patients with Castleman disease and collected from researcher around the world.
[6] Frits van Rhee and David Fajgenbaum discovered that "a drug that had been on the market for many years–Sirolimus–could be repurposed to fight Castleman Disease."
[13] Phase II (Ongoing) The team of volunteers continues to maintain an updated listing of all treatments reported to be used in COVID-19 patients from papers published in PubMed.